Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
Rhea-AI Summary
Candel Therapeutics (Nasdaq: CADL) announced that Dr. Francesca Barone, Chief Scientific Officer, will present and take part in panels at the 7th Annual Glioblastoma Drug Development Summit in Boston, Feb 17–19, 2026. Presentations will cover the HSV-based platform and linoserpaturev (CAN-3110) program in recurrent high-grade glioma, focusing on biomarker-driven clinical development, imaging integration, and biomarker-based enrollment strategies to inform patient stratification and response assessment.
Positive
- None.
Negative
- None.
News Market Reaction – CADL
On the day this news was published, CADL declined 3.99%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.4% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $324M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CADL slipped -0.17% with muted volume while key biotech peers CAPR, ANNX, MNPR, TNXP, and VNDA showed larger single-day declines between about -1.58% and -3.22%. No peers appeared in the momentum scanner and no same-day peer headlines were recorded, pointing to stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Inducement grant | Neutral | +0.8% | Inducement stock option grant to a new employee under 2025 Inducement Plan. |
| Nov 17 | R&D event announcement | Positive | -2.3% | Announcement of virtual R&D event detailing viral immunotherapy pipeline. |
| Nov 13 | Earnings and pipeline | Positive | -6.3% | Q3 2025 results plus CAN‑2409 Phase 3 data and CAN‑3110 survival update. |
| Nov 04 | Scientific conference data | Positive | -1.7% | SITC 2025 presentations on CAN‑2409, NSCLC biomarkers, and AI‑designed candidate. |
| Nov 03 | Investor conference | Neutral | -3.0% | Jefferies Global Healthcare Conference presentation announcement and webcast details. |
Recent clinically focused and corporate events often saw negative next-day moves, even when updates appeared fundamentally constructive.
Over the last few months, CADL has highlighted clinical progress and corporate visibility events. A Q3 2025 update on Nov 13 detailed CAN‑2409 Phase 3 success, CAN‑3110 survival data, and funding into Q1 2027, yet shares fell 6.3%. Data presentations at SITC 2025 on Nov 4 also preceded a modest decline. Conference appearance news on Nov 3 and a virtual R&D event announcement on Nov 17 similarly coincided with negative price reactions, while a small inducement grant on Feb 2, 2026 saw a mild gain.
Regulatory & Risk Context
An effective Form S-3 filed on Aug 14, 2025 allows Candel to offer up to $300,000,000 of securities, including up to $50,000,000 of common stock under an at-the-market program with Jefferies LLC. No usage has been recorded yet, but this facility provides flexibility to raise capital for working capital, R&D, manufacturing, clinical trials, or acquisitions.
Market Pulse Summary
This announcement highlights Candel’s scientific visibility, with its Chief Scientific Officer presenting CAN-3110 and biomarker-driven strategies at a glioblastoma summit on Feb 17–19, 2026. Recent filings show substantial cash of $87.2M as of 9/30/25, a $130.0M term loan facility, and a $300,000,000 shelf plus $50,000,000 ATM that provide capital flexibility. Investors may watch for subsequent clinical data updates, regulatory milestones, and any use of these financing tools.
Key Terms
glioblastoma medical
HSV-based medical
omics medical
molecular subtyping medical
biomarker-driven medical
Phase I/II medical
biomarker-based medical
clinical trial medical
AI-generated analysis. Not financial advice.
NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Francesca Barone, M.D., Ph.D., Candel’s Chief Scientific Officer, will present data and participate in multiple sessions at the 7th Annual Glioblastoma Drug Development Summit, taking place February 17-19, 2026 in Boston, Massachusetts.
Dr. Barone will share insights from Candel’s HSV-based platform and the linoserpaturev (CAN-3110) program in recurrent high-grade glioma (rHGG) through workshop presentations and panel discussions focused on advancing biomarker-driven clinical development in glioblastoma.
Details are as follows:
Workshop Panel
Title: Harnessing Omics Data & Molecular Subtyping to Inform Patient Stratification in Clinical & Translational Strategies in Glioblastoma Drug Development
Date/Time: Tuesday, Feb. 17, 2026, 8:00 a.m. ET
Conference Presentation
Title: Integration of Biomarkers & Imaging to Define Patient Response in a Phase I/II Clinical Trial
Date/Time: Wednesday, Feb. 18, 2026, 9:30 a.m. ET
Panel Discussion
Title: Driving the Use of Biomarker-Based Enrollment in GBM Trials to Accelerate Clinical Success & Improve Patient Outcomes
Date/Time: Wednesday, Feb. 18, 2026, 12:00 p.m. ET
About linoserpaturev (CAN-3110)
CAN-3110 is a first-in-class, replication-competent, next-generation oncolytic herpes simplex virus-1 (HSV-1) immunotherapy candidate designed for dual activity for oncolysis and immune activation in a single therapeutic. In October 2023, the Company announced that Nature published results from the ongoing clinical trial where linoserpaturev was reported to be generally well tolerated with no dose-limiting toxicity. In the clinical trial, the investigators observed improved median overall survival compared to historical controls after a single linoserpaturev injection in this therapy-resistant condition.1 The Company and academic collaborators are currently supported by the Break Through Cancer foundation to evaluate the effects of repeated linoserpaturev injections in patients with recurrent glioblastoma in an expansion cohort from the phase 1b clinical trial. In October 2025, Science Translational Medicine presented findings from the comprehensive analysis of 97 serial tumor biopsies collected from two patients treated with repeated administrations of linoserpaturev in arm C. Linoserpaturev previously received Fast Track Designation and Orphan Drug Designation for the treatment of recurrent HGG from the U.S. Food and Drug Administration (FDA).
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation for the treatment of PDAC.
Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent HGG. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, including the timing and availability of additional data and key data readout milestones and presentations; expectations regarding early biological readouts as predictor of clinical response; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, each as filed with the SEC, and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
Vice President
ICR Healthcare
CandelPR@icrhealthcare.com
1 Ling AL, et al. Nature. 2023;623(7985):157-166
FAQ
When will Candel Therapeutics (CADL) present at the Glioblastoma Drug Development Summit in 2026?
What topics will CADL present about CAN-3110 (linoserpaturev) at the Feb 2026 summit?
Which CADL presentation at the summit covers biomarkers and imaging to define patient response?
What is CADL's session on biomarker-based enrollment and when is it scheduled?
Where and when is the workshop on omics data and molecular subtyping by CADL scheduled?
